

Global health R&D: What's at stake during the 69th WHA?

Speaker biographies

Dr David Kaslow

David Kaslow, MD, oversees PATH's product development programs—Devices and Tools, Diagnostics, Drug Development, the Malaria Vaccine Initiative (MVI), Vaccine Access and Delivery, and Vaccine Development—as well as PATH's work in China, which focuses on product development activities. As the leader of the PATH Center for Vaccine Innovation and Access, he oversees PATH's work to accelerate the development and introduction of lifesaving vaccines for the most vulnerable children and communities around the world.

Dr Kaslow has more than 25 years of experience in vaccine research and development (R&D). Before joining PATH in 2012 as Director of MVI's work to drive the development of safe and effective vaccines against malaria, he held key advisory positions with MVI and the Bill & Melinda Gates Foundation related to malaria vaccines. Prior to that, he oversaw project leadership and management of Merck Research Laboratories' vaccine pipeline and founded the Malaria Vaccine Development Unit at the National Institutes of Health.

As a basic research scientist, Dr Kaslow completed the molecular cloning and characterization of several proteins involved in malaria parasite sexual development. He has also directed product development, including field studies, of several malaria vaccine candidates. Outside the malaria field, Dr Kaslow has contributed to the vaccine application of tools originally developed for gene therapy. He holds or coholds more than a dozen patents and has published more than 150 scientific papers. Dr Kaslow received his medical degree from the University of California, San Francisco.

Dr Marie-Paule Kieny

Dr Marie-Paule Kieny, PhD, was appointed Assistant Director-General at the World Health Organization (WHO) in October 2010 and is now leading the Health Systems and Innovation cluster.

Prior to this, Dr Kieny directed the WHO Initiative for Vaccine Research since its inception in 2001. Major successes under her leadership were the development and licensing of new vaccines against meningitis and against pandemic influenza in developing countries through pioneering the transfer of technology and know-how. During 2015-2016, Dr Kieny led WHO's Ebola research activities. She is currently in charge of Zika R&D in WHO as well as of the preparation of an R&D Blueprint to accelerate global research preparedness for future outbreaks.

Before coming to WHO, Dr Kieny held top research positions in the public and private sectors of her home country, France. The positions included Assistant Scientific Director of Transgene S.A. from 1981 to 1988, and Director of Research and Head of the Hepatitis C Virus Molecular Virology Group at the Institute of Virology, Institut national de la santé et de la recherche médicale (INSERM) from 1999 to 2000.

She received her PhD in Microbiology from the University of Montpellier in 1980, where she was also awarded a University Diploma in Economics, and her Diplôme d'Habilitation à Diriger des Recherches from the University of Strasbourg in 1995.

Dr Suerie Moon

Suerie Moon, MPA, PhD, is Research Director and Cochair of the Forum on Global Governance for Health at the Harvard Global Health Institute. She is also a Lecturer in the Department of Global Health and Population at the Harvard T.H. Chan School of Public Health, where she teaches masters and doctoral students on global governance and health.

Recently she served as the Study Director of the Independent Panel on the Global Response to Ebola, a joint initiative of Harvard and the London School of Hygiene and Tropical Medicine. She is also a member of the Expert Advisory Group to the UN Secretary-General's High-Level Panel on Access to Medicines. She co-directed the Project on Innovation and Access to Technologies for Sustainable Development at the Harvard Kennedy School of Government from 2011-2016. Her work focuses on global governance, the political economy of global health (with a focus on innovation and access to medicines; trade, investment and intellectual property rules; outbreak preparedness and response; and development assistance for health), the evolution of international regimes, and innovative policies for addressing global problems.

Dr Moon is a member of the editorial board of PLoS Medicine, Global Health Governance and Associate Editor of Global Challenges; Board of Directors of Doctors Without Borders/Médecins Sans Frontières USA; Board of Directors of the Drugs for Neglected Diseases *initiative* North America; and expert member of the Proposal Review Committee of UNITAID. Her work has appeared in a number of highly-ranked academic journals; she speaks regularly at public events, to the media and at legislative hearings; and consults for a number of nongovernmental organizations, think tanks, and intergovernmental organizations on global governance and access to medicines issues.

She received a BA in History from Yale University, an MPA from the Woodrow Wilson School of Public and International Affairs at Princeton University, and a PhD in Public Policy from the Harvard Kennedy School of Government.

Dr Bernard Pécoul

Dr Bernard Pécoul, MD, MPH, has led the Drugs for Neglected Diseases *initiative* (DNDi) since its foundation in 2003. Under his guidance, DNDi—a nonprofit R&D organization—with hundreds of public and private partners, has delivered six new treatments for the most neglected diseases (leishmaniasis, sleeping sickness, and Chagas disease) and for malaria. It has developed a robust portfolio of projects spanning from discovery to implementation for these diseases as well as filaria, pediatric HIV, mycetoma, and hepatitis C. As part of DNDi's dynamic portfolio approach, Dr Pécoul is also leading the incubation of a product development partnership to address R&D for new antibiotic treatments.

DNDi aims to deliver a total of 16 to 18 new treatments for neglected patients by 2023, with a total of €650 million, spanning 10 disease areas. The initiative, through its R&D work, also builds capacity in disease endemic countries through research platforms and technology transfers and advocates for greater public leadership to sustainably address the health needs of neglected patients.

Prior to DNDi, Dr Pécoul was Director of the Médecins Sans Frontières (MSF) Campaign for Access to Essential Medicines from 1998 to 2003, a position he took on after that of Executive Director of MSF-France. While working with MSF, Dr Pécoul carried out field missions in Africa, Latin America, and Asia. In 1988, he cofounded Epicentre, an MSF-affiliated nongovernmental organization specialized in epidemiology.

After obtaining his medical degree at the University of Clermont-Ferrand, France, Dr Pécoul earned a master's degree in Public Health at Tulane University, United States of America. In 2012, he was awarded an honorary Doctor of Laws Degree by the University of Dundee, United Kingdom.

Bernard Pécoul is member of the Joint Coordination Board of the Special Programme for Tropical Disease Research (WHO/TDR) and a board member of UNITAID's Medicines Patent Pool.

Ambassador Guilherme Patriota

Guilherme de Aguiar Patriota is Deputy Permanent Representative of Brazil to the United Nations and other international organizations in Geneva.

A career diplomat since 1983, he has been a delegate of Brazil accredited to the Organization of American States in Washington (1990 to 1994); the Latin American Integration Association, in Montevideo (1994 to 1997); the Embassy of Brazil in New Zealand (1997 to 2000); the World Trade Organization and the World Intellectual Property Organization, in Geneva (2005 to 2008); and twice to the United Nations in New York (2008 to 2010; 2013 to 2015). He was International Advisor to the Brazilian Minister of Science and

Technology (2003 to 2004) and Deputy Foreign Policy Advisor to the President of the Republic (2010 to 2013).

Ambassador Patriota was a graduate student in Biological Sciences at the Federal University of Rio de Janeiro and at the Federal University of Brasilia, and obtained his higher-level degree with the Brazilian Diplomatic Academy on the theme of Brazilian Scientific and Technological Diplomacy.

Joelle Tanguy

Joelle Tanguy is currently Executive in Residence at the Geneva Centre for Security Policy and supervisory board member of the Access to Medicine Index Foundation.

Joelle was most recently Under-Secretary General of the International Red Cross and Red Crescent Federation, and led humanitarian diplomacy activities including for key crises such as the Ebola epidemic.

She had previously served as Managing Director at Gavi, the Vaccine Alliance, in charge of External Relations and she orchestrated the organization's first financial replenishment securing US\$4.3 billion (above target) at the height of the fiscal crisis.

Joelle also served as Executive Director of Médecins Sans Frontières/Doctors without Borders USA, Executive Vice President for Ambassador Richard Holbrooke's Global Business Coalition on HIV/AIDS, and Founding Director of Advocacy and Public Policy of the TB Alliance.

Joelle has been a member of board and advisory committees of The Global Fund to Fight AIDS, Tuberculosis and Malaria; Médecins Sans Frontières; and Human Rights Watch. She is now serving as a board member for the Access to Medicine Index Foundation and the Drugs for Neglected Diseases *initiative*.

Joelle lived in France, USA, Japan, Armenia, Uganda, Guatemala, Somalia, Bosnia, and Switzerland, some of those as head of humanitarian missions, often at the height of political and military turmoil.

Joelle studied business at HEC MBA in France and at the Stanford Graduate School of Business in California. She received her MBA from HEC MBA in a joint program with Stanford University, and worked with technology ventures in California, Europe, and Japan, before volunteering on humanitarian missions after an eye-opening sabbatical trip across Asia.